Health Condition 1: I509- Heart failure, unspecified
Conditions
Interventions
Intervention1: NIL: NIL
Control Intervention1: NIL: NIL
Sponsors
Cipla Limited
Eligibility
Inclusion criteria
Inclusion criteria: Patients of either gender or aged more than 18 years Patients with documented heart failure with reduced left ventricular ejection fraction less than 40 percent not more than 3 months prior to enrolment Patients with NYHA class II IV and not hospitalized in the past 1 month prior to enrolment ARNi naïve symptomatic, chronic HFrEF patients which includes recently diagnosed patients OR stable chronic HFrEF patients Patients eligible for initiation of ARNi therapy as per the clinical judgement of the treating physician Provide written informed consent
Exclusion criteria
Exclusion criteria: Patients who are deemed ineligible for this study at the discretion of the treating physician Pregnant and Lactating female Patients with acute decompensated heart failure Patients with Hyperkalemia potassium level more than or equal to 5.30 mmol per Litres within the past 2 weeks Patients are currently participating in another clinical study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the dosage pattern and treatment persistence with ARNi therapy in HFrEF patients in IndiaTimepoint: Baseline and 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| To describe the medication dosage pattern and the implementation of GDMT in HFrEF patients who are initiated with ARNi To evaluate the safety of ARNi therapy To evaluate the effectiveness of ARNi therapyTimepoint: Baseline and 12 weeks | — |
Countries
India
Contacts
Public ContactDr Nitin Zalte
Cipla Ltd
Outcome results
None listed